Emerging synthetic cannabinoids detected by a drug checking service in Toronto, Canada.

BACKGROUND

Toronto's Drug Checking Service (DCS) provides people who use drugs with information on the chemical composition of their substances and conducts real-time monitoring of the unregulated drug supply. Presented are first known data of three newly detected synthetic cannabinoids (SCs) in Toronto, Ontario.

METHODS

The present data are from samples analyzed between April and November 2020. Samples were collected at partnering harm reduction agencies in Toronto and analyzed using gas or liquid chromatography-mass spectrometry. An intake survey queried about the sample characteristics on submission, including expected drug(s).

RESULTS

Samples were analyzed between 1 April and 20 November 2020 ( = 19), which marks the period immediately following imposed COVID-19 border and movement restrictions in Canada. The newly detected, unexpected SCs were ACHMINACA ( = 15), AB-FUBINACA ( = 3), and 4-fluoro-MDMB-BUTINACA ( = 1). Fentanyl was expected in 74% ( = 14). Most SCs were detected in samples containing fentanyl or related analogues ( = 18; 95%), or benzodiazepine-related drugs (i.e., etizolam and flualprazolam) ( = 15; 79%).

CONCLUSIONS

This information can inform overdose prevention efforts and drug market monitoring of SCs in Toronto and regions served by the same drug trafficking routes. The detection of SCs during a period marked by COVID-19-related restrictions can contribute to efforts to identify global drug market trends during this time.